Table 5 Effectiveness of the BNT162b2 and mRNA-1273 vaccines against any severe⁹, critical⁹, or fatal¹⁰ COVID-19.

Sub-studies^a	BNT162b2					mRNA-1273
	Cases^b (Severe, critical, or fatal disease)^c		Controls^b (PCR-negative)		Effectiveness in % (95% CI)^d	Cases^b (Severe, critical, or fatal disease)^c		Controls^b (PCR-negative)		Effectiveness in % (95% CI)^d
	Vaccinated		Vaccinated			Vaccinated		Vaccinated
	Yes	No	Yes	No		Yes	No	Yes	No
Dose 1
Dose 1 and no Dose 2	2	111	8	290	40.9 (−199.1 to 88.3)	0	110	3	287	100.0 (Omitted)^e
Dose 2
1–6 months after Dose 2 and no Dose 3	14	123	108	261	70.4 (45.0 to 84.0)	2	113	34	272	87.1 (40.2 to 97.2)
≥7 months after Dose 2 and no Dose 3	76	143	461	218	77.5 (67.8 to 84.3)	23	126	148	264	68.4 (46.1 to 81.5)
Dose 3 (booster dose)
1–6 weeks after Dose 3	8	125	143	257	90.9 (78.6 to 96.1)	1	110	18	280	81.8 (−49.5 to 97.8)
≥7 weeks after Dose 3	12	134	197	254	90.1 (80.6 to 95.0)	0	110	3	287	100.0 (Omitted)^e

CI confidence interval, PCR polymerase chain reaction.
^aIn each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.
^bCases and controls were matched one-to-five by sex, 10-year age group, nationality, and calendar week of PCR test.
^cSeverity⁹, criticality⁹, and fatality¹⁰ were defined as per World Health Organization guidelines.
^dVaccine effectiveness was estimated using the test-negative, case–control study design^11,12.
^eConfidence interval could not be estimated using conditional logistic regression because of zero events among those vaccinated.

Quick links

Search